Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA1 | P00915 | 7/20 | 0.52 |
| ▸ | CA2 | P00918 | 7/20 | 0.52 |
| ▸ | CA9 | Q16790 | 4/20 | 0.48 |
| ▸ | NT5E | P21589 | 3/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.45 |
| ▸ | CA12 | O43570 | 3/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.45 |
| ▸ | PKM | P14618 | 1/20 | 0.45 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | PDPK1 | O15530 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 2/20 | 0.44 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | TGM2 | P21980 | 1/20 | 0.43 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Gw275616X SCHEMBL4839162 | 1.00 | CA1 (0.52) | CA1CA2CA9NT5EPOLB | |
| SCHEMBL7899300 | 0.86 | POLB (0.55) | CA1CA2CA9NT5EPOLB | |
| SCHEMBL4994672 | 0.86 | POLB (0.55) | CA1CA2CA9NT5EPOLB | |
| SCHEMBL4991565 | 0.82 | ALK (0.50) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL4991559 | 0.82 | ALK (0.50) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL4996412 | 0.80 | PRKCA (0.50) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL4996402 | 0.80 | PRKCA (0.50) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL3811533 | 0.80 | MAPT (0.58) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL3811532 | 0.80 | MAPT (0.58) | MAPTALDH1A1KDM4EPKMMAPK1 | |
| SCHEMBL14822865 | 0.80 | MAPT (0.58) | MAPTALDH1A1KDM4EPKMMAPK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7338966-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | claimed |
| US-20050228025-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | DICKERSON SCOTT H | 2005-10-13 | — | — | US | claimed |
| US-20030195234-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | claimed |
| US-7338966-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338966-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7338966-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2008-03-04 | — | — | US | disclosed |
| US-7071217-B2 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION (US) | 2006-07-04 | — | — | US | disclosed |
| US-20050228025-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | DICKERSON SCOTT H | 2005-10-13 | — | — | US | disclosed |
| US-20030195234-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | SMITHKLINE BEECHAM CORPORATION | 2003-10-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030195234-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | FRK, LTK, ERBB2 | CA1 4845/4885CA2 4400/4885CA9 4805/4885 |
| US-20050228025-A1 | Substituted oxindole derivatives as tyrosine kinase inhibitors | LTK, FRK, ERBB2 | CA1 4776/4885CA2 3828/4885CA9 4563/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.